Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Acasti Pharma Inc logo
    ACST

    Acasti Pharma Inc

    MaveScore 12 Low model confidence
    Last Price US$3.37 As of Updating
    Market Cap US$31.7m Company size context
    7D Performance 1.20% Past 7 days
    1Y Performance 44.64% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Updating

    Refreshing

    Market price date

    Updating

    Refreshing

    Coverage

    7/16

    9 missing model inputs

    Data quality

    Limited

    Limited stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 12 Low confidence

    Stored data quality

    Freshness and coverage checks

    7/16 Limited stored snapshot

    Quality

    10/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    0/25 Needs Data

    Financial strength needs live profitability and cash-flow fields.

    Valuation Support

    0/15 Needs Data

    Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    Momentum

    0/15 Needs Data

    Momentum needs recent 3-month or 6-month price-change data.

    Shareholder Alignment

    2/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Financial strength needs live profitability and cash-flow fields.
    • Valuation needs price plus per-share earnings, cash-flow, or book-value inputs.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include return on equity, net margin, gross margin, free cash flow per share, book value per share, earnings per share, latest price, 3-month price change, 6-month price change.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Acasti Pharma Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Read More

    Acasti Pharma Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Acasti Pharma Inc

    Score

    Reported Results

    No latest earnings report cached yet

    Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

    Recent News



    Earnings Per Share

    Score 0.00/5
    Acasti Pharma Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.84/5
    Acasti Pharma Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
    Acasti Pharm... ACST US$31.7m

    Net Margin

    Score 2.10/5
    Acasti Pharma Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
    Acasti Pharm... ACST US$31.7m

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 1.53/5
    Acasti Pharma Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including have achieved high scores.
    Acasti Pharm... ACST US$31.7m

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Acasti Pharma Inc logo

    Acasti Pharma Inc

    US$3.37

    US$31.7m

    1.20%

    44.64%